Suberoylanilide hydroxamic acid (SAHA) and cladribine synergistically induce apoptosis in NK-LGL leukaemia

British Journal of Haematology

Volumn 168, Issue 3, 2015, Pages 371-383

  Sun, Xiaoshen ^a,b   Hasanali, Zainul S ^c   Chen, Allshine ^c   Zhang, Dianzheng ^d   Liu, Xin ^c   Wang, Hong Gang ^c   Feith, David J ^b   Loughran, Thomas P ^b   Xu, Kailin ^a  

^a XUZHOU MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF VIRGINIA   (United States)

^c PENN STATE COLLEGE OF MEDICINE   (United States)

^d PHILADELPHIA COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

Author keywords

Cladribine; Combined epigenetic therapy; Histone deacetylation; Natural killer large granular lymphocyte leukaemia; Vorinostat (suberoylanilide hydroxamic acid)

Indexed keywords

APOPTOSIS INDUCING FACTOR; APOPTOTIC PROTEASE ACTIVATING FACTOR 1; CASPASE 3; CASPASE 8; CASPASE 9; CD70 ANTIGEN; CLADRIBINE; FAS ANTIGEN; FAS ASSOCIATED DEATH DOMAIN PROTEIN; FAS LIGAND; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 10; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 5; HISTONE DEACETYLASE 8; HISTONE DEACETYLASE 9; INTERLEUKIN 1BETA CONVERTING ENZYME; MESSENGER RNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN MCL 1; STAT3 PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; VORINOSTAT; ANTINEOPLASTIC AGENT; HISTONE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; RNA;

AGGRESSIVE NK CELL LEUKEMIA; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL DEATH; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; EPIGENETICS; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; HISTONE ACETYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LARGE GRANULAR LYMPHOCYTE LEUKEMIA; LEUKEMIA; LOW DRUG DOSE; NATURAL KILLER CELL; NATURAL KILLER LARGE GRANULAR LYMPHOCYTE LEUKAEMIA; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ACETYLATION; DOSE RESPONSE; DRUG EFFECTS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; LEUKEMIA, LARGE GRANULAR LYMPHOCYTIC; METABOLISM; PATHOLOGY; PROCEDURES; TUMOR CELL CULTURE;

ACETYLATION; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CLADRIBINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; EPIGENESIS, GENETIC; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HISTONES; HUMANS; HYDROXAMIC ACIDS; LEUKEMIA, LARGE GRANULAR LYMPHOCYTIC; RNA, MESSENGER; RNA, NEOPLASM; TUMOR CELLS, CULTURED;

EID: 84921434066     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13143     Document Type: Article

References (61)

1. Akiyama, T., Dass, C.R. & Choong, P.F. (2009) Bim-targeted cancer therapy: a link between drug action and underlying molecular changes. Molecular Cancer Therapeutics, 8, 3173-3180.
2. Arzenani, M.K., Zade, A.E., Ming, Y., Vijverberg, S.J., Zhang, Z., Khan, Z., Sadique, S., Kallenbach, L., Hu, L., Vukojevic, V. & Ekstrom, T.J. (2011) Genomic DNA hypomethylation by histone deacetylase inhibition implicates DNMT1 nuclear dynamics. Molecular and Cellular Biology, 31, 4119-4128.
3. Betticher, D.C., von Rohr, A., Ratschiller, D., Schmitz, S.F., Egger, T., Sonderegger, T., Herrmann, R., Kroner, T., Zulian, G.B., Cavalli, F., Fey, M.F. & Cerny, T. (1998) Fewer infections, but maintained antitumor activity with lower-dose versus standard-dose cladribine in pretreated low-grade non-Hodgkin's lymphoma. Journal of Clinical Oncology, 16, 850-858.
4. Blattmann, C., Oertel, S., Thiemann, M., Weber, K.J., Schmezer, P., Zelezny, O., Lopez Perez, R., Kulozik, A.E., Debus, J. & Ehemann, V. (2012) Suberoylanilide hydroxamic acid affects gammaH2AX expression in osteosarcoma, atypical teratoid rhabdoid tumor and normal tissue cell lines after irradiation. Strahlentherapie und Onkologie, 188, 168-176.
5. Bolden, J.E., Peart, M.J. & Johnstone, R.W. (2006) Anticancer activities of histone deacetylase inhibitors. Nature Reviews. Drug Discovery, 5, 769-784.
6. Bosanquet, A.G., Sturm, I., Wieder, T., Essmann, F., Bosanquet, M.I., Head, D.J., Dorken, B. & Daniel, P.T. (2002) Bax expression correlates with cellular drug sensitivity to doxorubicin, cyclophosphamide and chlorambucil but not fludarabine, cladribine or corticosteroids in B cell chronic lymphocytic leukemia. Leukemia, 16, 1035-1044.
7. Butler, L.M., Agus, D.B., Scher, H.I., Higgins, B., Rose, A., Cordon-Cardo, C., Thaler, H.T., Rifkind, R.A., Marks, P.A. & Richon, V.M. (2000) Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Research, 60, 5165-5170.
8. Byrd, J.C., Peterson, B., Piro, L., Saven, A., Vardiman, J.W., Larson, R.A. & Schiffer, C. (2003) A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211. Leukemia, 17, 323-327.
9. Carbone, E., Ruggiero, G., Terrazzano, G., Palomba, C., Manzo, C., Fontana, S., Spits, H., Karre, K. & Zappacosta, S. (1997) A new mechanism of NK cell cytotoxicity activation: the CD40-CD40 ligand interaction. Journal of Experimental Medicine, 185, 2053-2060.
10. Ceruti, S., Beltrami, E., Matarrese, P., Mazzola, A., Cattabeni, F., Malorni, W. & Abbracchio, M.P. (2003) A key role for caspase-2 and caspase-3 in the apoptosis induced by 2-chloro-2′-deoxy-adenosine (cladribine) and 2-chloro-adenosine in human astrocytoma cells. Molecular Pharmacology, 63, 1437-1447.
11. Chen, S., Zhao, Y., Gou, W.F., Zhao, S., Takano, Y. & Zheng, H.C. (2013) The anti-tumor effects and molecular mechanisms of suberoylanilide hydroxamic acid (SAHA) on the aggressive phenotypes of ovarian carcinoma cells. PLoS ONE, 8, e79781.
12. Cheson, B.D., Vena, D.A., Foss, F.M. & Sorensen, J.M. (1994) Neurotoxicity of purine analogs: a review. Journal of Clinical Oncology, 12, 2216-2228.
13. Chou, T.C. & Talalay, P. (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Advances in Enzyme Regulation, 22, 27-55.
14. Chowdhury, S., Howell, G.M., Teggart, C.A., Chowdhury, A., Person, J.J., Bowers, D.M. & Brattain, M.G. (2011) Histone deacetylase inhibitor belinostat represses survivin expression through reactivation of transforming growth factor beta (TGFbeta) receptor II leading to cancer cell death. Journal of Biological Chemistry, 286, 30937-30948.
15. Cohen, I., Poreba, E., Kamieniarz, K. & Schneider, R. (2011) Histone modifiers in cancer: friends or foes? Genes & Cancer, 2, 631-647.
16. De Paepe, M.E., Gundavarapu, S., Tantravahi, U., Pepperell, J.R., Haley, S.A., Luks, F.I. & Mao, Q. (2008) Fas-ligand-induced apoptosis of respiratory epithelial cells causes disruption of postcanalicular alveolar development. American Journal of Pathology, 173, 42-56.
17. Dong, G., Wang, L., Wang, C.Y., Yang, T., Kumar, M.V. & Dong, Z. (2008) Induction of apoptosis in renal tubular cells by histone deacetylase inhibitors, a family of anticancer agents. Journal of Pharmacology and Experimental Therapeutics, 325, 978-984.
18. Edelman, M.J., O'Donnell, R.T. & Meadows, I. (1997) Treatment of refractory large granular lymphocytic leukemia with 2-chlorodeoxyadenosine. American Journal of Hematology, 54, 329-331.
19. Epling-Burnette, P.K., Liu, J.H., Catlett-Falcone, R., Turkson, J., Oshiro, M., Kothapalli, R., Li, Y., Wang, J.M., Yang-Yen, H.F., Karras, J., Jove, R. & Loughran, T.P. Jr (2001) Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. The Journal of Clinical Investigation, 107, 351-362.
20. Epling-Burnette, P.K., Bai, F., Wei, S., Chaurasia, P., Painter, J.S., Olashaw, N., Hamilton, A., Sebti, S., Djeu, J.Y. & Loughran, T.P. (2004) ERK couples chronic survival of NK cells to constitutively activated Ras in lymphoproliferative disease of granular lymphocytes (LDGL). Oncogene, 23, 9220-9229.
21. Fandy, T.E., Shankar, S., Ross, D.D., Sausville, E. & Srivastava, R.K. (2005) Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma. Neoplasia, 7, 646-657.
22. Fenaux, P., Mufti, G.J., Hellstrom-Lindberg, E., Santini, V., Finelli, C., Giagounidis, A., Schoch, R., Gattermann, N., Sanz, G., List, A., Gore, S.D., Seymour, J.F., Bennett, J.M., Byrd, J., Backstrom, J., Zimmerman, L., McKenzie, D., Beach, C. & Silverman, L.R. (2009) Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncology, 10, 223-232.
23. Gillings, A.S., Balmanno, K., Wiggins, C.M., Johnson, M. & Cook, S.J. (2009) Apoptosis and autophagy: BIM as a mediator of tumour cell death in response to oncogene-targeted therapeutics. FEBS Journal, 276, 6050-6062.
24. Griffiths, E.A. & Gore, S.D. (2008) DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes. Seminars in Hematology, 45, 23-30.
25. Henderson, C., Mizzau, M., Paroni, G., Maestro, R., Schneider, C. & Brancolini, C. (2003) Role of caspases, Bid, and p53 in the apoptotic response triggered by histone deacetylase inhibitors trichostatin-A (TSA) and suberoylanilide hydroxamic acid (SAHA). Journal of Biological Chemistry, 278, 12579-12589.
26. Hirsch, C.L., Ellis, D.J. & Bonham, K. (2010) Histone deacetylase inhibitors mediate post-transcriptional regulation of p21WAF1 through novel cis-acting elements in the 3′ untranslated region. Biochemical and Biophysical Research Communications, 402, 687-692.
27. Holler, N., Zaru, R., Micheau, O., Thome, M., Attinger, A., Valitutti, S., Bodmer, J.L., Schneider, P., Seed, B. & Tschopp, J. (2000) Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nature Immunology, 1, 489-495.
28. Huang, D.C., Hahne, M., Schroeter, M., Frei, K., Fontana, A., Villunger, A., Newton, K., Tschopp, J. & Strasser, A. (1999) Activation of Fas by FasL induces apoptosis by a mechanism that cannot be blocked by Bcl-2 or Bcl-x(L). Proceedings of the National Academy of Sciences of the United States of America, 96, 14871-14876.
29. Jones, P.L., Veenstra, G.J., Wade, P.A., Vermaak, D., Kass, S.U., Landsberger, N., Strouboulis, J. & Wolffe, A.P. (1998) Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nature Genetics, 19, 187-191.
30. Kalyaanamoorthy, S. & Chen, Y.P. (2013) Energy based pharmacophore mapping of HDAC inhibitors against class I HDAC enzymes. Biochimica et Biophysica Acta, 1834, 317-328.
31. Kim, P.K., Park, S.Y., Koty, P.P., Hua, Y., Luketich, J.D. & Billiar, T.R. (2003) Fas-associating death domain protein overexpression induces apoptosis in lung cancer cells. Journal of Thoracic and Cardiovascular Surgery, 125, 1336-1342.
32. Kluin-Nelemans, H.C., Oldhoff, J.M., Van Doormaal, J.J., Van 't Wout, J.W., Verhoef, G., Gerrits, W.B., van Dobbenburgh, O.A., Pasmans, S.G. & Fijnheer, R. (2003) Cladribine therapy for systemic mastocytosis. Blood, 102, 4270-4276.
33. Kretzner, L., Scuto, A., Dino, P.M., Kowolik, C.M., Wu, J., Ventura, P., Jove, R., Forman, S.J., Yen, Y. & Kirschbaum, M.H. (2011) Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and microRNA levels. Cancer Research, 71, 3912-3920.
34. Lamy, T. & Loughran, T.P. (1998) Large granular lymphocyte leukemia. Cancer Control, 5, 25-33.
35. Lamy, T., Liu, J.H., Landowski, T.H., Dalton, W.S. & Loughran, T.P. Jr (1998) Dysregulation of CD95/CD95 ligand-apoptotic pathway in CD3(+) large granular lymphocyte leukemia. Blood, 92, 4771-4777.
36. Leone, G., D'Alo, F., Zardo, G., Voso, M.T. & Nervi, C. (2008) Epigenetic treatment of myelodysplastic syndromes and acute myeloid leukemias. Current Medicinal Chemistry, 15, 1274-1287.
37. Lim, M.S., de Leval, L. & Quintanilla-Martinez, L. (2009) Commentary on the 2008 WHO classification of mature T- and NK-cell neoplasms. Journal of Hematopathology, 2, 65-73.
38. Liu, X., Ryland, L., Yang, J., Liao, A., Aliaga, C., Watts, R., Tan, S.F., Kaiser, J., Shanmugavelandy, S.S., Rogers, A., Loughran, K., Petersen, B., Yuen, J., Meng, F., Baab, K.T., Jarbadan, N.R., Broeg, K., Zhang, R., Liao, J., Sayers, T.J., Kester, M. & Loughran, T.P. Jr (2010) Targeting of survivin by nanoliposomal ceramide induces complete remission in a rat model of NK-LGL leukemia. Blood, 116, 4192-4201.
39. Liu, J., Zhang, X., Liu, A., Liu, S., Zhang, L., Wu, B. & Hu, Q. (2013) Berberine induces apoptosis in p53-null leukemia cells by down-regulating XIAP at the post-transcriptional level. Cellular Physiology and Biochemistry, 32, 1213-1224.
40. Maes, K., Menu, E., Van Valckenborgh, E., Van Riet, I., Vanderkerken, K. & De Bruyne, E. (2013) Epigenetic modulating agents as a new therapeutic approach in multiple myeloma. Cancers, 5, 430-461.
41. Marks, P.A., Richon, V.M. & Rifkind, R.A. (2000) Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. Journal of the National Cancer Institute, 92, 1210-1216.
42. Nan, X., Ng, H.H., Johnson, C.A., Laherty, C.D., Turner, B.M., Eisenman, R.N. & Bird, A. (1998) Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature, 393, 386-389.
43. O'Brien, S., Kurzrock, R., Duvic, M., Kantarjian, H., Stass, S., Robertson, L.E., Estey, E., Pierce, S. & Keating, M.J. (1994) 2-Chlorodeoxyadenosine therapy in patients with T-cell lymphoproliferative disorders. Blood, 84, 733-738.
44. Perez-Galan, P., Marzo, I., Giraldo, P., Rubio-Felix, D., Lasierra, P., Larrad, L., Anel, A. & Naval, J. (2002) Role of caspases and apoptosis-inducing factor (AIF) in cladribine-induced apoptosis of B cell chronic lymphocytic leukemia. Leukemia, 16, 2106-2114.
45. Rahmani, M., Anderson, A., Habibi, J.R., Crabtree, T.R., Mayo, M., Harada, H., Ferreira-Gonzalez, A., Dent, P. & Grant, S. (2009) The BH3-only protein Bim plays a critical role in leukemia cell death triggered by concomitant inhibition of the PI3K/Akt and MEK/ERK1/2 pathways. Blood, 114, 4507-4516.
46. Robak, T. & Robak, P. (2012) Purine nucleoside analogs in the treatment of rarer chronic lymphoid leukemias. Current Pharmaceutical Design, 18, 3373-3388.
47. Robertson, M.J., Cochran, K.J., Cameron, C., Le, J.M., Tantravahi, R. & Ritz, J. (1996) Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia. Experimental Hematology, 24, 406-415.
48. Roger, P.M., Bernard-Pomier, G., Counillon, E., Breittmayer, J.P., Bernard, A. & Dellamonica, P. (1999) Overexpression of Fas/CD95 and Fas-induced apoptosis in a patient with idiopathic CD4+ T lymphocytopenia. Clinical Infectious Diseases, 28, 1012-1016.
49. Romine, J.S., Sipe, J.C., Koziol, J.A., Zyroff, J., McMillan, R. & Beutler, E. (1997) Cladribine. BioDrugs, 7, 386-393.
50. Sarkar, S., Abujamra, A.L., Loew, J.E., Forman, L.W., Perrine, S.P. & Faller, D.V. (2011) Histone deacetylase inhibitors reverse CpG methylation by regulating DNMT1 through ERK signaling. Anticancer Research, 31, 2723-2732.
51. Sharma, S., Kelly, T.K. & Jones, P.A. (2009) Epigenetics in cancer. Carcinogenesis, 31, 27-36.
52. Sigal, D.S., Miller, H.J., Schram, E.D. & Saven, A. (2010) Beyond hairy cell: the activity of cladribine in other hematologic malignancies. Blood, 116, 2884-2896.
53. Spurgeon, S.E., Pindyck, T., Okada, C., Chen, Y., Chen, Z., Mater, E., Abbi, K. & Epner, E.M. (2011) Cladribine plus rituximab is an effective therapy for newly diagnosed mantle cell lymphoma. Leukemia & Lymphoma, 52, 1488-1494.
54. Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., Thiele, J. & Vardiman, J.W. (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn. International Agency for Research on Cancer Press, Lyon, France.
55. Teramo, A., Gattazzo, C., Passeri, F., Lico, A., Tasca, G., Cabrelle, A., Martini, V., Frezzato, F., Trimarco, V., Ave, E., Boscaro, E., Piazza, F., Facco, M., Trentin, L., Semenzato, G. & Zambello, R. (2013) Intrinsic and extrinsic mechanisms contribute to maintain the JAK/STAT pathway aberrantly activated in T-type large granular lymphocyte leukemia. Blood, 121, S3841.
56. Thurn, K.T., Thomas, S., Moore, A. & Munster, P.N. (2011) Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer. Future Oncology, 7, 263-283.
57. Wang, D., Jing, Y., Ouyang, S., Liu, B., Zhu, T., Niu, H. & Tian, Y. (2013) Inhibitory effect of valproic acid on bladder cancer in combination with chemotherapeutic agents in vitro and in vivo. Oncology Letters, 6, 1492-1498.
58. Willimott, S. & Wagner, S.D. (2010) Post-transcriptional and post-translational regulation of Bcl2. Biochemical Society Transactions, 38, 1571-1575.
59. Yang, F.C., Agematsu, K., Nakazawa, T., Mori, T., Ito, S., Kobata, T., Morimoto, C. & Komiyama, A. (1996) CD27/CD70 interaction directly induces natural killer cell killing activity. Immunology, 88, 289-293.
60. Yue, P. & Turkson, J. (2009) Targeting STAT3 in cancer: how successful are we? Expert Opinion on Investigational Drugs, 18, 45-56.
61. Zhang, C., Richon, V., Ni, X., Talpur, R. & Duvic, M. (2005) Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. Journal of Investigative Dermatology, 125, 1045-1052.